TRIM68 is an E3 ubiquitin ligase that functions as a critical coactivator of androgen receptor (AR) signaling. In prostate cancer, TRIM68 enhances AR-mediated transcription through ligand-dependent mechanisms, cooperating with coactivators TIP60 and p300, and its overexpression increases PSA secretion while knockdown inhibits cell growth 1. TRIM68 stabilizes target proteins through K63-linked polyubiquitination; notably, it stabilizes MOAP1 in lung cancer, suppressing NSCLC proliferation, migration, and metastasis through apoptosis induction and EMT inhibition 2. In prostate cancer, TRIM68 expression is regulated by m6A methylation reader YTHDF1, linking epigenetic modifications to androgen-dependent progression 3. Beyond oncology, TRIM68 negatively regulates innate immunity by targeting TRK-fused gene (TFG) for lysosomal degradation, thereby limiting type I interferon production downstream of TLR and RIG-I signaling 4. TRIM68 emerges as a prognostic biomarker in osteosarcoma, correlating with immune cell infiltration 5, tuberculosis-associated immune responses 6, and triple-negative breast cancer progression 7. Collectively, TRIM68 functions as a multifaceted ubiquitin ligase with tissue-specific roles in androgen signaling, apoptosis regulation, and immune modulation.